Last reviewed · How we verify

Dexamethasone+ Bupivacaine

Ain Shams University · FDA-approved active Small molecule

Dexamethasone+ Bupivacaine is a Corticosteroid + Local anesthetic combination Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Local anesthesia with anti-inflammatory effect for regional anesthesia and pain management, Periarticular or perineural injection to reduce postoperative pain and inflammation.

Dexamethasone reduces inflammation and immune response while bupivacaine provides local anesthesia by blocking nerve conduction.

Dexamethasone reduces inflammation and immune response while bupivacaine provides local anesthesia by blocking nerve conduction. Used for Local anesthesia with anti-inflammatory effect for regional anesthesia and pain management, Periarticular or perineural injection to reduce postoperative pain and inflammation.

At a glance

Generic nameDexamethasone+ Bupivacaine
SponsorAin Shams University
Drug classCorticosteroid + Local anesthetic combination
TargetGlucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)
ModalitySmall molecule
Therapeutic areaPain management, Anesthesia, Inflammation
PhaseFDA-approved

Mechanism of action

Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production. Bupivacaine is a local anesthetic that blocks sodium channels in nerve membranes, preventing action potential propagation. Together, this combination provides both local pain relief and anti-inflammatory effects at the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexamethasone+ Bupivacaine

What is Dexamethasone+ Bupivacaine?

Dexamethasone+ Bupivacaine is a Corticosteroid + Local anesthetic combination drug developed by Ain Shams University, indicated for Local anesthesia with anti-inflammatory effect for regional anesthesia and pain management, Periarticular or perineural injection to reduce postoperative pain and inflammation.

How does Dexamethasone+ Bupivacaine work?

Dexamethasone reduces inflammation and immune response while bupivacaine provides local anesthesia by blocking nerve conduction.

What is Dexamethasone+ Bupivacaine used for?

Dexamethasone+ Bupivacaine is indicated for Local anesthesia with anti-inflammatory effect for regional anesthesia and pain management, Periarticular or perineural injection to reduce postoperative pain and inflammation.

Who makes Dexamethasone+ Bupivacaine?

Dexamethasone+ Bupivacaine is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What drug class is Dexamethasone+ Bupivacaine in?

Dexamethasone+ Bupivacaine belongs to the Corticosteroid + Local anesthetic combination class. See all Corticosteroid + Local anesthetic combination drugs at /class/corticosteroid-local-anesthetic-combination.

What development phase is Dexamethasone+ Bupivacaine in?

Dexamethasone+ Bupivacaine is FDA-approved (marketed).

What are the side effects of Dexamethasone+ Bupivacaine?

Common side effects of Dexamethasone+ Bupivacaine include Local injection site reactions, Transient nerve irritation, Systemic corticosteroid effects (with repeated use), Allergic reactions to bupivacaine.

What does Dexamethasone+ Bupivacaine target?

Dexamethasone+ Bupivacaine targets Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine) and is a Corticosteroid + Local anesthetic combination.

Related